Both Sackner-Bernstein and his co-author, Keith Aaronson of the University of Michigan, worked under Milton Packer at one time.
In one negotiation, Bernstein name-checks Miles Davis in order to telegraph his worth to another man.
In a statement, Jonathan Sackner-Bernstein, a New York cardiologist who co-authored the papers that warned of Natrecor's alleged safety risks, wrote that the results provide hope that there will be new therapies for acute heart failure.
The Redwood String Ensemble's story lies in the stage, and - like Bernstein, Barber, and Copland - the beauty of our art lies in the truth of our identity.
The study's lead author, Jonathan Sackner-Bernstein of North Shore University Hospital in Manhassett, N.
Forbes.com covered Sackner-Bernstein's concerns in February, and they have since been published in major medical journals.
Study co-author Jonathan Sackner-Bernstein, director of the clinical research at North Shore University Hospital in Manhasset, N.
Bernstein mixes well-known pop songs with a lost style of jazz that predates the big band era.
Sackner-Bernstein's data indicate Natrecor increases the risk of kidney enzyme elevation, a warning sign for damage, by 40% or more.
"Everybody who does medical research knows that just because you think something should work doesn't mean that it will, " Sackner-Bernstein says.
Sackner-Bernstein and Aaronson have been raising concerns about Natrecor for more than two years, and Natrecor has been approved since 2001.
Packer's unease springs from the work of Jonathan Sackner-Bernstein , a heart failure expert at North Shore University Hospital in Manhasset, N.
"This is a study that raises a concern about safety, " says Sackner-Bernstein.
Reached for comment, Jonathan Sackner-Bernstein of the research firm CliniLabs said that he "always hoped to be proved wrong" about the safety worries.
Safety issues about Natrecor were raised by Jonathan Sackner-Bernstein , a New York cardiologist, and Keith Aaronson , a researcher at the University of Michigan.
Two years ago a pair of cardiologists, Jonathan Sackner-Bernstein and Keith Aaronson, published a series of papers arguing that Natrecor was not safe, based on existing clinical trials.
Sackner-Bernstein says he started out as an "enthusiast" for Natrecor.
But Sackner-Bernstein says that the data seem to support the view that drugs that help acute heart failure symptoms in the short term can do harm in the long term.
Jonathan Sackner-Bernstein, of the clinical research outfit CliniLabs, says that data on Merck's drug rolofylline "look pretty impressive, " although he does worry about seizures or other side effects cropping up in late-stage trials.
Undaunted, CHF's Erb hopes to begin selling machines to outpatient clinics, though another skeptic, Jonathan Sackner-Bernstein at CliniLabs in New York, says that rollout is "premature, " preferring its use be kept at hospitals.
In an accompanying editorial, John Teerlink and Barry Massie, both cardiologists at the University of California, San Francisco, write that Sackner-Bernstein's data, though extremely limited, sheds an important light on the way drugs are approved and prescribed.
At medical meetings and in the journals Circulation and The Journal of the American Medical Association, Jonathan Sackner-Bernstein of North Shore University Hospital and Keith Aaronson of the University of Michigan fretted that Natrecor might cause kidney problems or even an increase in mortality.
Sackner-Bernstein dredged through Natrecor data that had already been published or submitted to the FDA. A first study, presented at the meeting of the American College of Cardiology in March 2003, showed an increase in mortality for patients using Natrecor, but didn't show a reason for the increased death rate.
Bernstein recently upgraded Bristol-Myers to an "outperform, " arguing that the market is ignoring one of the industry's better drug pipelines.
Also see The Power of Gold: The History of an Obsession by the late Peter Bernstein for a long-term view.
But short of such a radical scenario, pricing reform would not kill off innovation, according to Sanford Bernstein, a financial-research firm.
Mr Ensign's ideas on Social Security and public education look remarkably similar to George W. Bush's, and Mr Bernstein's prescription-drug plan comes straight from the Gore book.
Bernstein, said the Merck-Serono pairing seemed to make sense for investors in both companies.
The worse is still ahead for troubled Alcatel-Lucent, Bernstein Research analyst Pierre Ferrgu asserted in a research note Monday.
FORBES: Alcatel-Lucent: Bernstein Cuts Rating; Sees More Downside
应用推荐